A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Summary

The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.

Timeline

Start

2018-06-27

Primary completion

2020-06-25

Completion

2020-06-25

Drugs

Indications